1,100 Invokana Lawsuits Alleging Diabetic Ketoacidosis, Kidney Injury, Amputations and Heart Complications Now Pending in U.S. Courts, Bernstein Liebhard LLP Reports

NEW YORK, March 12, 2018 /PRNewswire/ -- Invokana lawsuits filed on behalf of individuals who developed life-threatening complications allegedly related to treatment with the Type 2 diabetes medication continue to mount in courts throughout the United States.

According to a February 22nd filing with the U.S. & Securities and Exchange Commission, Johnson & Johnson and its Janssen Pharmaceuticals unit have been named defendants in approximately 1,100 product liability claims involving Invokana, including hundreds of federally-filed cases that have been centralized in the U.S. District Court, District of New Jersey. Hundreds of additional Invokana lawsuits are pending in various state courts in Pennsylvania, California and New Jersey, while class action lawsuits have been filed in Canada.

Johnson & Johnson has established an accrual with respect to the Invokana litigation.

"Our firm is representing numerous individuals who suffered serious side effects allegedly related to Invokana, including diabetic ketoacidosis, heart attack and stroke, kidney injuries, and lower limb amputations. As we continue to be contacted by potential Invokana plaintiffs with similar claims, it is not at all surprising that the litigation involving this medication continues to grow at a significant rate," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to evaluate legal claims on behalf of Type 2 diabetes patients who were allegedly injured as result of Invokana.

Invokana Side Effects
Approved by the U.S. Food & Drug Administration (FDA) in March 2013, Invokana was the first SGLT2 inhibitor cleared by the agency for the treatment of Type 2 diabetes. Drugs in this class lower blood glucose levels by preventing the absorption of sugar by the kidneys, allowing it to be eliminated by the body via urine.

In December 2015, the FDA announced that the labels for all SGLT2 inhibitors would be updated to include information about diabetic ketoacidosis, a potentially deadly complication related to the accumulation of ketones in the bloodstream. The labels were also modified at that time with information about life-threatening blood infections (urosepsis) and kidney infections (pyelonephritis) that originate as urinary tract infections.

In June 2015, the FDA required  that the manufacturers of Invokana and several other SGLT2 inhibitors strengthen their labels' kidney warnings, after those medications were linked to more than 100 reports of acute kidney injury.

The Invokana label was updated once again in May 2017, after the FDA concluded that canagliflozin was associated with an increased risk of leg and foot amputations, mostly affecting the toes.

Bernstein Liebhard LLP continues provide free legal reviews to individuals who were allegedly harmed by Invokana. To learn more, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP  
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.

Bernstein Liebhard LLP 
10 East 40th Street 
New York, New York 10016 
800-511-5092

ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information: 
Sandy A. Liebhard, Esq. 
Bernstein Liebhard LLP 
info (at)consumerinjurylawyers(dot)com
http://www.rxinjuryhelp.com/  
https://plus.google.com/115936073311125306742?rel=author

SOURCE Bernstein Liebhard LLP